Jyoti Malhotra, MD, MPH

Dr. Malhotra is an Associate Professor in the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center. She is a thoracic medical oncologist and a member of the Developmental Therapeutics program. Dr. Malhotra’s expertise is in Experimental Therapeutics and she has led multiple phase I trials investigating novel agents and combinations for cancer therapy including first-in-human trials. Dr. Malhotra has a particular interest in novel approaches to combine immunotherapy with other agents for the treatment of lung cancer and refractory solid tumors. Dr. Malhotra has led multiple investigator-initiated clinical trials as well as a national trial sponsored by the National Cancer Institute- Cancer Therapy Evaluation Program (CTEP). She is also an active member of the SWOG cooperative group and serves on the NCCN panel for small cell lung cancer and IASLC Global Multidisciplinary Practice Standards Committee. Dr. Malhotra completed her residency in Internal Medicine at Georgetown University Hospital and Washington Hospital Center in Washington, DC and her fellowship in Hematology and Oncology at Mount Sinai Hospital in New York City.
Financial relationships
-
Attribution:SelfType of financial relationship:OtherIneligible company:Astra-ZenecaTopic:Advisory board memberDate added:04/18/2025Date updated:04/18/2025Relationship end date:02/21/2025
-
Attribution:SelfType of financial relationship:OtherIneligible company:Bristol Meyer SquibbTopic:Consultant on NSCLCDate added:04/18/2025Date updated:04/18/2025Relationship end date:02/19/2025
-
Attribution:SelfType of financial relationship:OtherIneligible company:Johnson & JohnsonTopic:Advisory board memberDate added:04/18/2025Date updated:04/18/2025
-
Attribution:SelfType of financial relationship:OtherIneligible company:Daiichi SankyoTopic:Advisory board memberDate added:04/18/2025Date updated:04/18/2025Relationship end date:12/06/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:BioatlaTopic:DSMC memberDate added:04/18/2025Date updated:04/18/2025
-
Attribution:SelfType of financial relationship:OtherIneligible company:AbbvieTopic:Advisory board memberDate added:04/18/2025Date updated:04/18/2025Relationship end date:09/07/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:RegeneronTopic:Consultant on NSCLCDate added:04/18/2025Date updated:04/18/2025Relationship end date:07/16/2024